Freestone Capital Holdings LLC reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 38.3% in the fourth quarter, HoldingsChannel reports. The firm owned 198,522 shares of the biopharmaceutical company’s stock after selling 123,325 shares during the quarter. Freestone Capital Holdings LLC’s holdings in Gilead Sciences were worth $12,417,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Bank of New York Mellon Corp raised its position in Gilead Sciences by 199,789.8% during the 3rd quarter. Bank of New York Mellon Corp now owns 31,350,714 shares of the biopharmaceutical company’s stock valued at $2,420,587,000 after purchasing an additional 31,335,030 shares during the last quarter. Oregon Public Employees Retirement Fund raised its position in Gilead Sciences by 5,733.7% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 28,988,297 shares of the biopharmaceutical company’s stock valued at $463,000 after purchasing an additional 28,491,386 shares during the last quarter. Capital Research Global Investors raised its position in shares of Gilead Sciences by 22.5% in the 3rd quarter. Capital Research Global Investors now owns 69,854,968 shares of the biopharmaceutical company’s stock worth $5,393,502,000 after acquiring an additional 12,818,301 shares in the last quarter. BlackRock Inc. raised its position in shares of Gilead Sciences by 2.2% in the 4th quarter. BlackRock Inc. now owns 104,186,077 shares of the biopharmaceutical company’s stock worth $6,516,839,000 after acquiring an additional 2,195,948 shares in the last quarter. Finally, TIAA CREF Investment Management LLC raised its position in shares of Gilead Sciences by 21.1% in the 3rd quarter. TIAA CREF Investment Management LLC now owns 10,241,394 shares of the biopharmaceutical company’s stock worth $790,738,000 after acquiring an additional 1,786,881 shares in the last quarter. Hedge funds and other institutional investors own 78.23% of the company’s stock.
Several brokerages have recently issued reports on GILD. ValuEngine raised Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, December 1st. BidaskClub raised Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Tuesday, December 4th. Citigroup reissued a “buy” rating and issued a $100.00 target price on shares of Gilead Sciences in a research report on Tuesday, February 5th. Wells Fargo & Co decreased their target price on Gilead Sciences from $95.00 to $89.00 and set an “outperform” rating for the company in a research report on Tuesday, February 5th. Finally, Zacks Investment Research lowered Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, January 23rd. Two research analysts have rated the stock with a sell rating, nine have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. Gilead Sciences currently has a consensus rating of “Hold” and a consensus target price of $82.56.
GILD stock opened at $64.79 on Friday. Gilead Sciences, Inc. has a twelve month low of $60.32 and a twelve month high of $80.90. The company has a debt-to-equity ratio of 1.19, a current ratio of 3.38 and a quick ratio of 3.29. The company has a market cap of $82.69 billion, a P/E ratio of 10.53, a P/E/G ratio of 4.08 and a beta of 1.16.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Monday, February 4th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.70 by ($0.26). Gilead Sciences had a net margin of 24.65% and a return on equity of 37.03%. The company had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.52 billion. During the same period last year, the business earned $1.78 EPS. The firm’s quarterly revenue was down 2.6% on a year-over-year basis. Equities research analysts forecast that Gilead Sciences, Inc. will post 6.23 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, March 28th. Stockholders of record on Friday, March 15th will be paid a $0.63 dividend. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.57. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.89%. The ex-dividend date is Thursday, March 14th. Gilead Sciences’s dividend payout ratio (DPR) is 37.07%.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by Ticker Report and is the property of of Ticker Report. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://www.tickerreport.com/banking-finance/4223756/freestone-capital-holdings-llc-cuts-stake-in-gilead-sciences-inc-gild.html.
Gilead Sciences Profile
Gilead Sciences, Inc discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Further Reading: Stock Symbols Definition, Examples, Lookup
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.